Effects of Chemotherapy and Other Anticancer Agent Shortages Linger
January 8th 2024Although the severity of the shortage of chemotherapy agents, particularly with the platinum-based therapies cisplatin and carboplatin, has receded from the heights seen earlier in 2023, clinicians are still dealing with its ramifications and having to strategically manage how they employ certain chemotherapies.
Read More
ASCO Special Report Outlines Progress in Reducing Cancer Disparities for LGBTQ+ Individuals
December 29th 2023Charles S. Kamen, PhD, MPH, discusses key developments and efforts that are planned and underway to further the progress that has been observed in terms of increasing cancer equity in sexual and gender minority individuals.
Read More
What Fellows Need to Know: Key Takeaways From ESMO 2023
December 26th 2023The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.
Read More
Patritumab Deruxtecan BLA Receives Priority Review in NSCLC
December 22nd 2023The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.
Read More
Development of EHR-Integrated Cancer Staging Module Identifies Barriers, Increases Discrete Capture
December 22nd 2023The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.
Read More
B7-H4 Offers Potential Treatment Target in a Variety of Solid Tumors
December 21st 2023The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.
Read More
Oncologists Explore Treatment Options in LGSOC, Look Toward Promising Future
December 20th 2023Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Read More
Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
Read More
Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy
December 12th 2023Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Read More
Ibrutinib Plus Venetoclax Confers PFS, Response Benefit in Relapsed/Refractory MCL
December 12th 2023Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.
Read More